GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT02089256

CompletedPhase 4

Effect of Repeated Administration of Liraglutide on Insulinogenic Indices

Lead sponsor

University of Tartu

Asset

Liraglutide

Intravenous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criterion

—

Primary endpoint

•The glucose-sensitivity of the beta cells

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02089256

Org study IDLI20/1101

Timeline

Milestones

Study first posted2014-03-17estimated

Last update posted2015-04-01estimated

Study start2014-06 (month precision)

Primary completion2015-03actual (month precision)

Study completion2015-03actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years

Maximum age50 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Weight 50-100 kg

Exclusion criteria

•Chronic disease

•Concomitant drug use

•Pregnancy or lactation

•Fasting glucose >6 mmol/L.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Other (unclassified)

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint/low confidence

Change in the glucose-sensitivity of the beta cells

Time frame:baseline, first dose, after 3-weeks on treatment

change from baseline, improvement

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

Effects on adrenal hormones

Time frame:baseline, acute administration, 3 weeks

change from baseline, descriptive

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers.
Diabetes therapy : research, treatment and education of diabetes and related disorders2023 Apr (month)PMID36800161doi:10.1007/s13300-023-01381-wvia clinicaltrials gov reference derived + pubmed nct search
Tolerance Does Not Develop Toward Liraglutide's Glucose-Lowering Effect.
The Journal of clinical endocrinology and metabolism2017 Jul 1PMID28379427doi:10.1210/jc.2017-00199via clinicaltrials gov reference derived + pubmed nct search
Liraglutide Treatment May Affect Renin and Aldosterone Release.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme2017 Jan (month)PMID27300475doi:10.1055/s-0042-109065via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.